First Time, Real World Experience with the UroLift® Device Closely Mimics the LIFT Trial Data: a Single Surgeon Experience
Campbell F. Bryson, MD; Daniel Kellner, MD
Yale New Haven Hospital, New Haven, CT
First time, real world experience with the UroLift® device closely mimics the LIFT trial data: a single surgeon experience
The prostatic urethral lift (PUL) therapy for moderate BPH has been evaluated through the L.I.F.T. study and has shown continued robust results. As physicians weigh economic factors with potential patient benefit, it is important to know that these results are generalizable to surgeons who were not a part of the original trial and who practice in a "real world" setting.
Materials and Methods
At a single surgical center, 29 men who had an AUA IPSS >12, with prostate volume 19-80cc, with no cystoscopic evidence of significant median lobe involvement underwent the UroLift® procedure by a single surgeon, using between 2 and 7 loads per procedure. All patients had the procedure performed under LMA general anesthesia. A representative from the device company was present at all procedures. Their AUASI, quality of life scores (QoL) and post void residual (PVR) were evaluated preoperatively, at 2 weeks and 2 months postoperatively. These results were compared to the published LIFT data with a student t test.
The prostatic urethral lift reduced AUA symptom index scores, improved QoL, and reduced post void residuals at both the two week and two month mark. These changes were similar and not statistically different than the LIFT trial at similar time points.
The L.I.F.T. trial, a multicenter randomized control trial, showed robust improvements in AUA SIS, and QoL for patients with the use of the prostatic urethral lift therapy. This result seems to be generalizable to individual surgeons who are new to the technique. This study lends evidence to the prostatic urethral lift becoming a useful tool in the armamentarium of BPH surgeons.
|N (paired)||Baseline||Change||N (paired)||Baseline||Change||p value comparison|
|AUASS||2 weeks||29||21.7+/- 5.9||-11.0 +/- 8.5||138||22.2 +/- 5.5||-4.3 +/-7.6||0.695|
|2-3 months||20||21.7+/- 5.9||-12.7 +/- 10.1||139||22.2 +/- 5.5||-11.1 +/- 7.7||0.939|
|QoL||2 weeks||28||4.8 +/-1.0||-3.0 +/- 2.2||139||4.6 +/- 1.1||-1 +/- 1.7||0.611|
|2-3 months||19||4.8 +/-1.0||-2.9 +/-2.1||139||4.6 +/- 1.1||-2.2 +/- 1.8||0.896|
|PVR||2 weeks||27||89 +/- 76||-43 +/-67||NA||NA||NA||NA|
|2-3 months||16||89 +/- 76||-29 +/-64||136||85.1 +/- 68.6||-9 +/- 85.7||0.937|
Back to 2018 Program